title: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
abstract: The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure--one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.
authors.affiliation: Division of Geographic Medicine and Infectious Diseases, Tufts University and Tufts Medical Center, Boston, Massachusetts 02111, USA. hboucher@tuftsmedicalcenter.org
authors.forename: Helen W
authors.initials: HW
authors.lastname: Boucher
authors.forename: George H
authors.initials: GH
authors.lastname: Talbot
authors.forename: John S
authors.initials: JS
authors.lastname: Bradley
authors.forename: John E
authors.initials: JE
authors.lastname: Edwards
authors.forename: David
authors.initials: D
authors.lastname: Gilbert
authors.forename: Louis B
authors.initials: LB
authors.lastname: Rice
authors.forename: Michael
authors.initials: M
authors.lastname: Scheld
authors.forename: Brad
authors.initials: B
authors.lastname: Spellberg
authors.forename: John
authors.initials: J
authors.lastname: Bartlett
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy*; D055808:Drug Discovery / Q000639:trends*; D024881:Drug Resistance, Bacterial; D006801:Humans; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents